BICX BioCorrx Inc

BioCorRx to Present at the LD Micro Invitational XII on June 7th

BioCorRx to Present at the LD Micro Invitational XII on June 7th

ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California. 

Management is scheduled to present on Tuesday, June 7, 2022, at 11:30 am PT / 2:30 pm ET. The presentation will be webcast live and available for replay at . Management will also be available for one-on-one meetings with qualified investors throughout the conference.   

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit  for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit .

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.



714-462-4880



Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304

Media Contact:

PhillComm Global

al

704.942.1557



EN
31/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

 PRESS RELEASE

BioCorRx Appoints Renowned Investment and Capital Markets Executive Lo...

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and he will assume the formal role as President on February 1, 2024. Mr. Lucido will remain a Member of the Board of Directors. Additionally, the Company announced that Brady...

 PRESS RELEASE

BioCorRx Reports Business Update for the Third Quarter of 2023

BioCorRx Reports Business Update for the Third Quarter of 2023 ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We believe that the high and sustained concentrations of naltrexone released by BICX104 hold the potential to significantly curtail ...

 PRESS RELEASE

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104...

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) pati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch